Defining The Role Of Reserve Stem Cells In Gastric Cancer
Funder
National Health and Medical Research Council
Funding Amount
$563,739.00
Summary
Over 800,000 deaths from stomach cancer occur annually. This often fatal disease is caused by chronic inflammation of the stomach lining. This proposal will investigate how stomach inflammation ‘reprograms’ a new type of 'cancer stem cell' to form tumours and evaluate ways to therapeutically target these cells to prevent disease. Collectively, these studies will inform new approaches for stomach cancer prevention and treatment.
Using Connective Tissue Stem Cells To Treat Human Disease.
Funder
National Health and Medical Research Council
Funding Amount
$419,180.00
Summary
In our recent Cell paper (January 15, 2015), we reported our discovery of two new adult stem cells. One of these, the osteochondroreticular (OCR) bone stem cell (pronounced “ocker” stem cell) has a particular affinity for developing cartilage. We are testing if this cell could be used as a new treatment for osteoarthritis. The second new stem cell we discovered, is called the iRSC, and lies within the intestine. We are studying this cell in the development and treatment of bowel cancer.
How Does The Tumour Suppressor: Nerfin-1 Prevent Dietary Dependent Tumour Growth?
Funder
National Health and Medical Research Council
Funding Amount
$630,942.00
Summary
The influence of diet has been linked to tumour growth for decades, however, there is little scientific evidence to support or disprove this. In this study, we will assess the effect of diet on tumours in fruit flies. The metabolic genes which regulate the growth of fly tumours will then be studied in human brain tumours. Our studies will ultimately shed light on how tissue growth is controlled by dietary intake, and have the potential to inform the way that we treat and manage human cancers.
Identification Of Clinically Significant Subtypes Of Head And Neck Cancer Cells
Funder
National Health and Medical Research Council
Funding Amount
$469,122.00
Summary
Squamous cell carcinoma of the head and neck region (HNSCC) is amongst the top 10 most prevalent cancers. It is a life threatening cancer that is associated with a mortality rate of approximately 40%. Whilst most patients are treated with a combination of surgery, radiation and chemotherapy a significant fraction of patients relapse and eventually succumb to the cancer. The molecular basis for relapse in these patients is still unknown. One possible explanation for treatment failure is the notio ....Squamous cell carcinoma of the head and neck region (HNSCC) is amongst the top 10 most prevalent cancers. It is a life threatening cancer that is associated with a mortality rate of approximately 40%. Whilst most patients are treated with a combination of surgery, radiation and chemotherapy a significant fraction of patients relapse and eventually succumb to the cancer. The molecular basis for relapse in these patients is still unknown. One possible explanation for treatment failure is the notion that the cancer contains biologically distinct subtypes of cancer cells. Some these cells may respond to therapy whilst a small fraction of cells may not. If this small fraction of resistant cells were able to divide and repopulate the tissue then this would provide an explanation for relapse in these patients. However, as yet no such data has been available to support this argument. Most recently, studies with another cancer called acute myelocytic leukaemia has shown that they do contain a small subtype of cancer cells that are resistant to therapy and can regenerate the disease in patients. These cells have been called tumour initiating cells (TIC). In this application we will use patient tumour samples to try to isolate TICs from HNSCC. We will first determine whether these TICs exist and whether they express markers of normal human stem cells. We will also test whether these TICs are more resistant to chemotherapeutics or radiation than the rest of the tumour cells. In addition we will enrich for these TICs and identify new protein markers that could be used to test patient samples before or after treatment. This would be of considerable assistance in making decisions about treatment choice or prognosis. Since TICs have not been reported in HNSCC previously their identification would lead to a considerable advance in our undesratnding of how these tumours form.Read moreRead less
Haematopoietic Stem Cells From Human Pluripotent Stem Cells: The Future Of Bone Marrow Transplantation
Funder
National Health and Medical Research Council
Funding Amount
$763,845.00
Summary
Blood stem cell transplantation is a vital therapy for patients with leukaemia following chemotherapy or for patients with bone marrow failure. Because many patients lack a donor, there is a need for an alternate source of stem cells. My laboratory will make blood stem cells from human pluripotent stem cells that will treat patients needing a transplant and will be a useful research tool to help us to understand what goes wrong in the blood system in a range of illnesses.
I am cellular immunologist determining the important host immune cell types and effector molecules that control tumour initiation, growth, and metastasis.
Adult and embryonic stem cells have enormous therapeutic potential. Haemopoietic stem cells have been the most intensely studied and widely used in a therapeutic setting, yet we have only a patchy knowledge of the genes required for their proliferation and survival. I will use classical genetic screens in the mouse to identify genes that regulate stem cell behaviour. I will analyse two existing mutant mouse strains with reduced numbers of haemopoietic stem cells, and execute a novel genetic scre ....Adult and embryonic stem cells have enormous therapeutic potential. Haemopoietic stem cells have been the most intensely studied and widely used in a therapeutic setting, yet we have only a patchy knowledge of the genes required for their proliferation and survival. I will use classical genetic screens in the mouse to identify genes that regulate stem cell behaviour. I will analyse two existing mutant mouse strains with reduced numbers of haemopoietic stem cells, and execute a novel genetic screen utilising mice with a defect in the self-renewal of adult haemopoietic and neural stem cells, to find mice with a recovered stem cell compartment.Read moreRead less